Abstract P100: Hemorrhagic Stroke in the Setting of COVID-19 is Associated With Anticoagulation Use

• Published in: Stroke (1970) 2021-03, Vol.52 (Suppl_1), p.AP100-AP100
• Main Authors: Kvernland, Alexandra, Kumar, Arooshi, Yaghi, Shadi, Raz, Eytan, Frontera, Jennifer, Lewis, Ariane, Czeisler, Barry, Kahn, D. Ethan, Zhou, Ting, Ishida, Koto, Torres, Jose L, Riina, Howard, Shapiro, Maksim, Nossek, Erez, Nelson, Peter K, Tanweer, Omar, Gordon, David, Jain, Rajan, Dehkharghani, Seena, Henninger, Nils, De Havenon, Adam H, Mac Grory, Brian, Lord, Aaron, Melmed, Kara R
• Format: Article
• Language: English
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/str.52.suppl_1.P100

IntroductionWhile the thrombotic complications of COVID-19 have been described, there are limited data on its implications in hemorrhagic stroke. The clinical characteristics, underlying stroke mechanism, and outcomes in this group of patients are especially salient as empiric therapeutic anticoagulation becomes increasingly common in the treatment and prevention of thrombotic complications of COVID-19. MethodsWe conducted a retrospective cohort study of patients with hemorrhagic stroke (both non-traumatic intracerebral hemorrhage and spontaneous non-aneurysmal subarachnoid hemorrhage) who were hospitalized between 3/1/20-5/15/20 at a NYC hospital system, during the coronavirus pandemic. We compared the demographic and clinical characteristics of patients with hemorrhagic stroke and COVID-19 to those without COVID-19 admitted to our hospital between 3/1/20-5/15/20 (contemporary controls) and 3/1/19-5/15/19 (historical controls), using Fischer’s exact test and non-parametric testing. We adjusted for multiple comparisons using the Bonferroni method. ResultsDuring the study period, 19 out of 4071 (0.5%) patients who were hospitalized with COVID-19 had hemorrhagic stroke on imaging. Of all COVID-19 with hemorrhagic stroke, only 3 had non-aneurysmal SAH without intraparenchymal hemorrhage. Among hemorrhagic stroke and COVID-19 patients, coagulopathy was the most common etiology (73.7%); empiric anticoagulation was started in 89.5% vs 4.2% of contemporary and 10.0% of historical controls (both with p =